Latest Breaking News On - Cellular therapy department - Page 4 : comparemela.com

MaaT Pharma to Host First Virtual R&D Day on June 7th, 2022

R&D Day will take place virtually on June 7th from 4:00 pm-6:00 pm (CEST)/ 3:00 pm-5:00 pm (GMT) 10:00 am-12:00 pm (EST) Event will feature expert-led discussions on the microbiome and its

Saint antoineFlorent malardMohamad mohtyHassane zarourFrances mcglothlinDepartment of internal medicineTrophic communications corporateCellular therapy departmentUniversity of pittsburgMelanoma immunotherapy researchSenior pr corporate communicationsUniversity hospital center regensburgSorbonne universityMicrobiome ecosystem therapiesMicrobiome ecosystemMaat pharma

MaaT Pharma Announces First Patient Dosed in Phase 3 ARES Trial Evaluating MaaT013 in Patients with Acute Graft-vs-Host-Disease

Pivotal Phase 3 clinical trial investigates the efficacy of lead Microbiome Ecosystem Therapy MaaT013 as third-line treatment in patients with steroid-resistant gastrointestinal acute Graft-versus-Host

United statesMohamad mohtyCellular therapy departmentDrug administrationTrophic communicationsSenior pr corporate communicationsEuropean society for bloodSorbonne universityEuropean unionCorporate communicationsEuropean medicines agencyPivotal phaseMicrobiome ecosystem therapy maatGraft versus host diseaseMicrobiome ecosystem therapySaint antoine hospital

MaaT Pharma Presents Promising Clinical Data from 76 Patients with Acute Graft-vs-Host-Disease Treated with MaaT013 at 63rd ASH Annual Meeting

Oral presentation at 63rd American Society of Hematology Annual Meeting includes results from the HERACLES Phase 2 trial in 24 patients with steroid-resistant Grade III-IV gastrointestinal acute

United statesFrance generalJohn weinbergFlorent malardMohamad mohtyCellular therapy departmentAmerican society of hematology annual meetingDrug administrationEarly access programTrophic communicationsProfessor at sorbonne universitySorbonne universityCorporate communicationsEuropean medicines agencyFinancial communicationsFrance early access program

MaaT Pharma Presents Promising Clinical Data from 76 Patients with Acute Graft-vs-Host-Disease Treated with MaaT013 at 63rd ASH Annual Meeting

MaaT Pharma Presents Promising Clinical Data from 76 Patients with Acute Graft-vs-Host-Disease Treated with MaaT013 at 63rd ASH Annual Meeting
morningstar.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from morningstar.com Daily Mail and Mail on Sunday newspapers.

United statesFrance generalJohn weinbergFlorent malardMohamad mohtyCellular therapy departmentAmerican society of hematology annual meetingDrug administrationEarly access programTrophic communicationsProfessor at sorbonne universitySorbonne universityCorporate communicationsEuropean medicines agencyFinancial communicationsFrance early access program

MaaT Pharma Will Host Investor Information Meeting Following Presentation at ASH Conference of Additional Results on MaaT013

Comments on results from HERACLES Phase 2 trial and from early access program (EAP) in gastrointestinal acute Graft-vs-Host-Disease (GI aGvHD) Company to also provide a corporate update during

United statesFrance generalMohamad mohtyDrjohn weinbergCellular therapy departmentDrug administrationEarly access programTrophic communicationsAmerican society of hematologySorbonne universityEuropean medicines agencyAmerican societyAnnual meetingMaat pharmaChief medical officerMaat pharmaand